

Interim decision reached on scheduling of CBD

ECS Botanics Ltd (ASX: **ECS** or the **Company**) is pleased to advise that the National Advisory Committee on Medicines Scheduling (ACMS) and Advisory Committee on Chemicals Scheduling (ACCS), both committees within Australia's Therapeutic Goods Administration (TGA), have announced today a decision to alter the schedule 4 listing of CBD.

The interim decision recommends CBD to be classified as schedule 3. This would see CBD available over-the-counter, that is without prescription, from pharmacies.

The second consultation period has a closing deadline of October 13 2020, with the announcement of the final decision on February 1 2021. From this date qualifying CBD products can be made available in Australia over the counter without a prescription.

ECS's outdoor grow medicinal cannabis project has a CBD focus and the Company is pleased to advise that the project is progressing, with construction having commenced. ECS looks forward to updating the market on its CBD project as it progresses, including how it will take advantage of the anticipated increased demand for CBD.

Additionally, ECS also looks forward to updating the market in regard to its hemp food business and its strategy to leverage the opportunity of hemp protein as an optimal, functional and high value plant protein source.

ECS Managing Director Alex Keach said:

"The regulatory environment and market are shifting in ECS's favour and we have a solid production base to leverage our plant-based business for medicinal and food, capturing the extraordinary and unique properties of industrial hemp & cannabis."

About ECS Botanics

ECS Botanics is an agribusiness and hemp food company, cultivating (own and contract growers) and processing hemp for the wholesale market and its own retail food brand. The company's main operations are conducted in Tasmania, Australia. ECS has the necessary licences to cultivate, supply and manufacture industrial hemp in Tasmania as well as a grower licence in Queensland. ECS holds import and export licences with the Office of Drug Control (ODC) as well as having been granted licences for the cultivation and manufacture of medicinal cannabis. ECS owns a farm in Tasmania for commercial cultivation of hemp, research and as the site of its next generation approach to medicinal cannabis. ECS owns a strategic stake in TapAgrico for the logistics, drying and storage of hemp seed.

For further information, please contact:

Alexander Keach
Managing Director
alex@ecsbotanics.com.au
+61 419 323 059

Jason Hine
Chief Operations Officer
jason@ecsbotanics.com.au
+61 419 922 259

Authorised on behalf of ECS by Alex Keach, Managing Director

Not investment advice

This Company announcement ("CA") does not constitute investment or financial product advice nor any recommendation to acquire Company shares. It is not intended to be used on the basis for making a financial decision, nor is it intended to constitute legal, tax, or accounting advice or opinion. Any references to, or explanations of, legislation, regulatory issues, benefits or any other legal commentary are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of the Company shares. The CA has been prepared without taking into account your investment objectives, financial situation or particular needs. No reliance may be placed for any purpose whatsoever on the Information or on its accuracy or completeness.

Forward looking statements

The CA may contain forward looking statements which are identified by words such as "may", "could", "believes", "estimates", "expects", "forecasts", "intends" and other similar words that involve risks and uncertainties. You should be aware that such statements are only estimates or predictions, which may be based on subjective judgments and assumptions as to future events, which may or may not occur and which are subject to inherent risks and uncertainties, many of which are beyond the control of the Company. Actual events or results may differ materially from the events or results expected or implied in any forward looking statement. No representation or warranty (whether express or implied) is made as to the accuracy or likelihood of fulfilment of any forward looking statement. Any forward looking statements included in this CA involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies and other factors.